The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/nivolumab (ipi/nivo) initiation and treatment responses in mRCC. A retrospective study of ipi/nivo-treated mRCC at two US academic cancer centers was conducted. A landmark analysis at week 6 was performed to assess the association between the change in NER and clinical responses (progression-free survival (PFS)/overall survival (OS)). Week 6 NER was modeled as a continuous variable, after log transformation (Ln NER), and a categorical variable by percent change. There were 150 mRCC patients included: 78% had clear cell histology, and 78% were IMDC intermediate/poor risk. In multivariable regression analysis, every decrease of 1 unit of Ln NER at week 6 was associated with improved PFS (adjusted hazard ratio (AHR): 0.78, p-value:0.005) and OS (AHR: 0.67, p-value: 0.002). When NER was modeled by percent change, decreased NER > 50% was associated with improved PFS (AHR: 0.55, p-value: 0.03) and OS (AHR: 0.37, p-value: 0.02). The decrease in week 6 NER was associated with improved PFS/OS in ipi/nivo-treated mRCC. Prospective studies are warranted to validate NER change as a biomarker to predict ICI responses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2022), 15 vom: 07. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yu-Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Eosinophil |
|---|
| Anmerkungen: |
Date Revised 26.04.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers14153830 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344732878 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344732878 | ||
| 003 | DE-627 | ||
| 005 | 20231226023448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14153830 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344732878 | ||
| 035 | |a (NLM)35954493 | ||
| 035 | |a (PII)3830 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yu-Wei |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A lower baseline neutrophil-to-eosinophil ratio (NER) has been associated with improved responses to immune checkpoint inhibitors (ICI)-treated metastatic renal cell carcinoma (mRCC). This study investigated the decrease in NER at week 6 after ipilimumab/nivolumab (ipi/nivo) initiation and treatment responses in mRCC. A retrospective study of ipi/nivo-treated mRCC at two US academic cancer centers was conducted. A landmark analysis at week 6 was performed to assess the association between the change in NER and clinical responses (progression-free survival (PFS)/overall survival (OS)). Week 6 NER was modeled as a continuous variable, after log transformation (Ln NER), and a categorical variable by percent change. There were 150 mRCC patients included: 78% had clear cell histology, and 78% were IMDC intermediate/poor risk. In multivariable regression analysis, every decrease of 1 unit of Ln NER at week 6 was associated with improved PFS (adjusted hazard ratio (AHR): 0.78, p-value:0.005) and OS (AHR: 0.67, p-value: 0.002). When NER was modeled by percent change, decreased NER > 50% was associated with improved PFS (AHR: 0.55, p-value: 0.03) and OS (AHR: 0.37, p-value: 0.02). The decrease in week 6 NER was associated with improved PFS/OS in ipi/nivo-treated mRCC. Prospective studies are warranted to validate NER change as a biomarker to predict ICI responses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NER | |
| 650 | 4 | |a eosinophil | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a kidney cancer | |
| 650 | 4 | |a neutrophil-to-eosinophil ratio | |
| 650 | 4 | |a renal cell carcinoma | |
| 700 | 1 | |a Tucker, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Landon C |e verfasserin |4 aut | |
| 700 | 1 | |a Yasin, Hesham A |e verfasserin |4 aut | |
| 700 | 1 | |a Ancell, Kristin K |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Beckermann, Kathryn E |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Nancy B |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Kaiser, Elizabeth G |e verfasserin |4 aut | |
| 700 | 1 | |a McAlister, Renee K |e verfasserin |4 aut | |
| 700 | 1 | |a Schaffer, Kerry R |e verfasserin |4 aut | |
| 700 | 1 | |a Wallace, Deborah E |e verfasserin |4 aut | |
| 700 | 1 | |a George, Daniel J |e verfasserin |4 aut | |
| 700 | 1 | |a Rathmell, W Kimryn |e verfasserin |4 aut | |
| 700 | 1 | |a Rini, Brian I |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Tian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 14(2022), 15 vom: 07. Aug. |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:15 |g day:07 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers14153830 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 15 |b 07 |c 08 | ||